Navigation Links
Quark Pharmaceuticals Presented At ARVO Data Showing That PF-04523655 Enters Retinal Cells And Elicits Its Pharmacologic Effect Via Target Gene Knock-Down Without Activating TLR3
Date:5/11/2009

FREMONT, Calif., May 11 /PRNewswire/ -- Quark Pharmaceuticals, Inc., a development-stage pharmaceutical company discovering and developing novel RNA interference (RNAi)-based therapeutics, today announced that Elena Feinstein, M.D., Ph.D., Chief Scientific Officer, presented a study titled, "PF-04523655 (REDD14NP), an siRNA Compound Targeting RTP801, Penetrates Retinal Cells Producing Target Gene Knockdown and Avoiding TLR3 Activation," at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting, taking place from May 3-7, 2009, in Fort Lauderdale, Florida. PF-04523655 is currently being studied by partners Pfizer and Quark in patients with diabetic macular edema (DME) and age-related macular degeneration (AMD).

The study presented at ARVO was performed in collaboration with Dr. Jayakrishna Ambati at the Department of Ophthalmology and Visual Sciences, University of Kentucky College of Medicine, Lexington, KY. The objective of the study was to determine whether PF-04523655, a synthetic chemically modified 19-bp siRNA, enters cells in the retina leading to downregulation of its target gene while avoiding activation of Toll Like Receptor 3 (TLR3). Previous studies from Dr. Ambati's laboratory have shown that unmodified 21-mer siRNA molecules exhibit antiangiogenic effects by inadvertently activating TLR3 rather than down-regulating expression of their target genes. Results obtained in vivo and in vitro indicated that PF-04523655 does enter cells in the retina and elicits its pharmacologic effect via target gene knock-down without activating TLR3.

Daniel Zurr, Ph.D., President and Chief Executive Officer, said, "We believe that the results presented at ARVO continue to substantiate our leadership in siRNA therapeutics, in particular Quark's ability to develop highly specific siRNA products and advance them through the clinic toward commercialization. Quark's ability to establish col
'/>"/>

SOURCE Quark Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Quark Pharmaceuticals to Participate in 9th Annual Beyond Genome Conference
2. FDA Approves Quark IND for DGFi, an siRNA Therapeutic Based on Silence Therapeutics Unique Proprietary Chemistry
3. Quark Pharmaceuticals Announces Poster Presentations at RNAi Europe 2008
4. Quark Pharmaceuticals to Present at American Society for Pharmacology and Experimental Therapeutics Annual Meeting
5. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
6. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
7. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
8. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
9. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
10. Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences
11. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... 30, 2014 BioHealth Innovation, Inc. ... biohealth innovations and increasing access to early-stage funding in ... venture capitalist, Tania Fernandez , Ph.D., has joined ... will be a member of the management team for ... to $50 million in seed and early-stage equity investments ...
(Date:9/30/2014)... CT (PRWEB) September 30, 2014 ... non-profit funder of Lyme disease research at universities, today ... researchers focused on the identification, treatment and cure for ... it had received the most applications in its history—over ... , “While we were pleased to receive so ...
(Date:9/30/2014)... New Jersey (PRWEB) September 30, 2014 ... it has been chosen by the Parenteral Drug ... (November 18 and 19, 2014) on container closure integrity ... container closure integrity test methods and philosophies detailed in ... – Integrity Evaluation. The course will span ...
(Date:9/29/2014)... Iraq and Afghanistan, more than 300,000 soldiers have returned ... by exposure to bomb blasts and in particular, ... traumatic brain injury can range from the mild, such ... in memory and cognition. , Since 2007, the ... and complexity of this problem, and has made significant ...
Breaking Biology Technology:Seasoned Life Sciences Venture Capitalist Tania Fernandez Joins BHI to Help Manage New BioHealth Gap Fund 2Lyme Research Alliance Awards Nearly $600,000 in New Grants 2Lyme Research Alliance Awards Nearly $600,000 in New Grants 3Lyme Research Alliance Awards Nearly $600,000 in New Grants 4Whitehouse Laboratories to Partner with PDA for Educational Course on Container Closure Integrity Testing 2Whitehouse Laboratories to Partner with PDA for Educational Course on Container Closure Integrity Testing 3Whitehouse Laboratories to Partner with PDA for Educational Course on Container Closure Integrity Testing 4Modeling shockwaves through the brain 2Modeling shockwaves through the brain 3Modeling shockwaves through the brain 4
... skin tests at once with minimal patient discomfort, ... Unit announced today the launch of the ComforTen(TM) ... The device features ten,surgical steel 1.2mm lancet tips, ... ComforTen is the only 10-test, self-loading,surgical steel testing ...
... Nov. 9 Cadence Pharmaceuticals,Inc. (Nasdaq: CADX ... commercializing proprietary product candidates principally,for use in the ... its,third quarter ended September 30, 2007 financial results ... 2007. Cadence management will host a conference ...
... Dose and Data from First Randomized ... N.J., Nov. 8 Bristol-Myers Squibb,Company (NYSE: BMY ... (FDA) has approved new labeling for SPRYCEL to include ... and safety and,efficacy data in a greater number of ...
Cached Biology Technology:HollisterStier Offers Comfort With New ComforTen(TM) Multiple Skin Testing Device 2HollisterStier Offers Comfort With New ComforTen(TM) Multiple Skin Testing Device 3Cadence Pharmaceuticals to Host Conference Call and Webcast to Discuss Third Quarter 2007 Financial Results 2FDA Approves New SPRYCEL(R) (Dasatinib) Product Labeling for Patients with Chronic-Phase CML 2FDA Approves New SPRYCEL(R) (Dasatinib) Product Labeling for Patients with Chronic-Phase CML 3FDA Approves New SPRYCEL(R) (Dasatinib) Product Labeling for Patients with Chronic-Phase CML 4FDA Approves New SPRYCEL(R) (Dasatinib) Product Labeling for Patients with Chronic-Phase CML 5FDA Approves New SPRYCEL(R) (Dasatinib) Product Labeling for Patients with Chronic-Phase CML 6FDA Approves New SPRYCEL(R) (Dasatinib) Product Labeling for Patients with Chronic-Phase CML 7FDA Approves New SPRYCEL(R) (Dasatinib) Product Labeling for Patients with Chronic-Phase CML 8FDA Approves New SPRYCEL(R) (Dasatinib) Product Labeling for Patients with Chronic-Phase CML 9
(Date:9/30/2014)... The most comprehensive assessment conducted by the Ocean ... out of 100 in overall health. In addition, ... Antarctic and the 15 ocean regions beyond national ... maintaining a healthy climate, safeguarding biodiversity and providing ... update of the index, a partnership led by ...
(Date:9/30/2014)... 30, 2014--Sea monkeys have captured the popular attention of ... observable life cycle -- sold as dehydrated eggs, these ... little more than a tank of salt water. ... Like other zooplankton, brine shrimp vertically migrate in large ... to the surface at night and retreating deeper during ...
(Date:9/30/2014)... and Howard Hughes Medical Institute investigator, and Margarita ... in the 2014 round of grants from the ... (Brain Research through Advancing Innovative Neurotechnologies) Initiative for ... 30, provides more than $3 million in funding ... The BRAIN Initiative, launched last year, is a ...
Breaking Biology News(10 mins):Rating the planet's oceans 2Rating the planet's oceans 3Laser-guided sea monkeys show how zooplankton migrations may affect global ocean currents 2Salk scientists receive $3 million for BRAIN Initiative grant 2
... release is available in Spanish . , Agricultural ... wheat straw into ethanol "gold," and learning more about the ... production. At the ARS National Center for Agricultural ... conducted a 5-year study that examined whether wheat straw--a crop ...
... WASHINGTON, DC Fascinating advances across the spectrum ... be featured and explained through engaging table-top exhibits ... 16th Annual Exhibition and Reception. The exhibition/reception will ... Wednesday, April 14, in Rooms B338-340 of the ...
... old excuse, "I am only overweight because of my ... more evidence that the way our bodies digest and ... for every person. The budding discipline of metabolomics strives ... scientists and food chemists at the Technische Universitaet Muenchen ...
Cached Biology News:Cellulosic ethanol: Expanding options, identifying obstacles 2Science returns to Capitol Hill spotlight at April 14 exhibition 2Science returns to Capitol Hill spotlight at April 14 exhibition 3Science returns to Capitol Hill spotlight at April 14 exhibition 4Metabolic fingerprints offer fresh clues and a new path toward personalized medicine 2Metabolic fingerprints offer fresh clues and a new path toward personalized medicine 3
Mouse monoclonal [6G11] to Cytohesin 1 + 2 ( Abpromise for all tested applications)....
HNF-1 Purified Anti-Mouse, Anti-Rat, Anti-Rabbit, Anti-Human clone 2, Isotype Mouse IgG 1 , 50 µg Consult technical datasheet for details....
Recombinant Porcine IL-1 alpha/IL-1F1, CF...
... siRNA Custom Synthesis Service provides ... RNA to knockdown any gene. ... RNA base pairs with terminal ... or other lengths of your ...
Biology Products: